Outpatient Treatment with Lisocabtagene Maraleucel (liso-cel) in 3 Ongoing Clinical Studies in Relapsed/Refractory (R/R) Large B Cell Non-Hodgkin Lymphoma (NHL), Including Second-Line Transplant Noneligible (TNE) Patients: Transcend NHL 001, Outreach, and PILOT | Zendy

Carlos Bachier | Zendy; M. Lia Palomba | Zendy; Jeremy S. Abramson | Zendy; Charalambos Andreadis | Zendy; Alison R. Sehgal | Zendy; John E. Godwin | Zendy; Gerhard Hildebrandt | Zendy; Tanya Siddiqi | Zendy; Don A. Stevens | Zendy; Thalia A. Farazi | Zendy; Ana Kostić | Zendy; Nikolaus S. Trede | Zendy; Lei Wang | Zendy; James Lymp | Zendy; Tennille D. Thelen | Zendy; K. OGASAWARA | Zendy; David G. Maloney | Zendy

Open Access

Outpatient Treatment with Lisocabtagene Maraleucel (liso-cel) in 3 Ongoing Clinical Studies in Relapsed/Refractory (R/R) Large B Cell Non-Hodgkin Lymphoma (NHL), Including Second-Line Transplant Noneligible (TNE) Patients: Transcend NHL 001, Outreach, and PILOT

Author(s) -

Carlos Bachier,

M. Lia Palomba,

Jeremy S. Abramson,

Charalambos Andreadis,

Alison R. Sehgal,

John E. Godwin,

Gerhard Hildebrandt,

Tanya Siddiqi,

Don A. Stevens,

Thalia A. Farazi,

Ana Kostić,

Nikolaus S. Trede,

Lei Wang,

James Lymp,

Tennille D. Thelen,

K. OGASAWARA,

David G. Maloney

Publication year - 2020

Publication title -

biology of blood and marrow transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.301

H-Index - 120

eISSN - 1523-6536

pISSN - 1083-8791

DOI - 10.1016/j.bbmt.2019.12.093

Subject(s) - medicine , tocilizumab , fludarabine , rituximab , lymphoma , cyclophosphamide , cytokine release syndrome , surgery , oncology , chemotherapy , immunotherapy , cancer , chimeric antigen receptor , disease

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research